Nasiriyah

Researchers are evaluating the use of three blood biomarkers—the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)—to better diagnose and monitor preeclampsia, a serious pregnancy complication characterized by high blood pressure and potential organ damage. This condition affects 2-8% of pregnancies worldwide and is linked to placental dysfunction and abnormal blood vessel development. Current clinical indicators have limitations, so this study aims to improve early detection and treatment monitoring through these biomarkers. The study focuses on measuring the levels of these biomarkers in pregnant women between 20 and 36 weeks of gestation. The sFlt-1/PlGF ratio reflects an imbalance in proteins involved in blood vessel growth, with higher ratios indicating a higher risk of preeclampsia. Soluble endoglin contributes to blood vessel dysfunction, and osteoprotegerin may indicate vascular damage or activation. Blood samples will be analyzed to assess the concentrations of these markers. Participants will be pregnant women aged 18 to 45 attending the study site antenatal clinic. Researchers will collect serum samples at enrollment to measure the biomarkers and assess their relationship with preeclampsia diagnosis and severity. The study aims to provide better tools for predicting and evaluating treatment responses in preeclampsia, potentially improving maternal and perinatal health outcomes.